Navigation Links
Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
Date:2/8/2013

sease.

ABH001 is comprised of allogenic neonatal dermal fibroblasts seeded on a poly(glycolide-co-L-lactide) scaffold, and is currently approved and marketed in the United States as a Class III medical device under the trade name Dermagraft® for the treatment of diabetic foot ulcers.

About Epidermolysis Bullosa (EB)

Epidermolysis Bullosa is a family of genetic skin fragility disorders, primarily clinically characterized by blistering of the skin in response to friction or minor trauma. Although genetically and phenotypically heterogeneous, the common factor in all EB patients is the near constant presence of skin erosions and wounds. Severe forms of EB cause patients to live with constant pain and scarring, and may be fatal.

About ABH001

ABH001 is a tissue-engineered, human fibroblast-derived dermal substitute generated by culturing human neonatal dermal fibroblasts onto a bioabsorbable polyglactin (PGLLA) mesh scaffold. The fibroblasts, which are grown onto the PGLLA mesh, secrete dermal collagen, other extracellular matrix proteins, growth factors, and cytokines, creating a three-dimensional human tissue containing metabolically active living cells. The final product consists of a well-developed dermal matrix and evenly dispersed neonatal dermal fibroblasts.

About Dermagraft

Dermagraft is indicated for use in the treatment of full-thickness diabetic foot ulcers greater than six weeks duration, which extend through the dermis, but without tendon, muscle, joint capsule, or bone exposure. Dermagraft should be used in conjunction with standard wound care regimens and in patients that have adequate blood supply to the involved foot. Dermagraft is contraindicated for use in ulcers that have signs of clinical infection or in ulcers with sinus tracts. Dermagraft is contraindicated in patients with known hypersensitivity to bovine products, as it may contain trace amounts of bovine p
'/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
11. ODT Forum Presents Regenerative Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... The participants committed to not only creating unique business ... adjusting, tweaking and testing virtual models and 3D test ... , “I enjoyed being involved as a judge,” stated ... showed a commendable range exploring the technical capabilities of ... and the creativity of the contestants.” , Array Architects ...
(Date:10/1/2014)... In response to its clients’ evolving ... training and consumer engagement challenges, digital agency ... to turn their clients’ visions into reality. New ... app creations, are now featured on its website ... Toyota, StudioPMG created a robust cross-platform mobile application ...
(Date:10/1/2014)... 2014 Award winning unified communications ... four new-hosted collaboration bundles that combine next generation ... conferencing experiences for low, flat rate fees. ... businesses have optimized solutions to meet their technology ... audio only minutes (1K, 5K, 10K increments) or ...
(Date:10/1/2014)... Francisco, California (PRWEB) October 01, 2014 ... from the National Science Foundation to expand their bioCAD/CAM ... to build and modify DNA. The Small Business Innovation ... commercialize the “j5” technology under exclusive license from the ... Joint BioEnergy Institute , an LBNL laboratory that ...
Breaking Biology Technology:Array Architects Challenges Staff to Create with 3D Printer 2Digital Agency Studio PMG Launches New Case Studies on Website 2SoundConnect Launches New Audio, Web and Video Bundles 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3
... Ltd. (OTCQB: DROP), the parent company of FUSE Science, Inc. ... superstar Tiger Woods that will feature FUSE Science as the ... Science Adam Adler are set to conduct their first interview ... at 12:30 p.m. during an exclusive interview with Darren Rovell. ...
... WaferGen Biosystems, Inc. (OTCBB:WGBS), an emerging genomic analysis ... nine months ended September 30, 2011 and announced a ... SmartChip System. "During the third quarter of ... the rapidly changing needs of the Life Sciences Research ...
... Phase I Single Dose Study Data ... Convergence Pharmaceuticals Limited ("Convergence"), the company focused ... medicines, today announces that the multiple ascending dose Phase ... channel blocker CNV2197944, for the treatment of chronic pain ...
Cached Biology Technology:Tiger Woods Gives Exclusive First Interview Since POWERED by FUSE Announcement! 2WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 2WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 3WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 4WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 5WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 6WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 7WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 8Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 2Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 3Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 4
(Date:9/30/2014)... of Health (NIH) awarded Lawrence Livermore National Laboratory ... array system that will enable researchers to better ... and scale. , LLNL,s grant-funded project is part ... BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative ... understanding of the human mind and uncover ways ...
(Date:9/30/2014)... can live in almost any aquatic environment on Earth, ... many species are pushed to the limit. The amount ... prove critical for how different species cope in the ... University of Gothenburg, published in the scientific journal ... change continues apace thanks to increasing levels of greenhouse ...
(Date:9/30/2014)... you want your doctor to know what goes wrong with ... good idea to know what "normal" actually is. That,s where ... of the FASEB Journal comes in. ... transcriptomea key set of molecules that can help scientists "see" ... time. What,s more, they found never-before-detected gene activity and that ...
Breaking Biology News(10 mins):NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3Shape up quickly -- applies to fish, too! 2Scientists identify which genes are active in muscles of men and women 2
... keyhole surgery can be reduced by giving the surgeons a ... with their operating instruments. This is made possible by designing ... feedback signals to the handle held by the surgeon. Delft ... a working prototype for this. Grasp force , ...
... (NYSE Amex: WYY ), a specialist ... announced that Daniel E. Turissini, WidePoint,s CTO, will ... Protection and Management Symposium on February 3, 2011 ... the Federation for Identity and Cross-Credentialing Systems (FiXs). ...
... Asthma is one of the world,s most common chronic diseases, ... by 2025 there could be an additional 100 million people with ... to changing environmental or lifestyle factors, and over the last 15 ... published in the in the February 2011 issue of the ...
Cached Biology News:New training instrument allows surgeon to feel grasp force in keyhole surgery 2WidePoint Corporation Sponsors Identity Protection and Management Symposium, February 3, 2011 2WidePoint Corporation Sponsors Identity Protection and Management Symposium, February 3, 2011 3More research needed on diet and environmental influences on childhood asthma 2More research needed on diet and environmental influences on childhood asthma 3
Incorporating the innovative InGaAs detection system the Cary 6000i is the worlds most advanced UV-Vis-NIR spectrophotometer delivering superior signal to noise performance and outstanding sensitivit...
... PAL label printer is portable, easy-to-use and makes ... Portable/Handheld Easy to use ... vial and slide sizes Time/Date stamp ... needs one Serialization feature makes you ...
Each 72-well MiniTray is low profile, with lid. Conical well shape, 10 l....
...
Biology Products: